grant
Promoting Kidney Transplantation Tolerance Through Novel Immunomodulation and Cellular Therapy
Organization UNIVERSITY OF MINNESOTALocation MINNEAPOLIS, UNITED STATESPosted 20 Apr 2023Deadline 31 Mar 2028
NIHUS FederalResearch GrantFY2025(TNF)-αAccelerationAffinityAgeAllograftingAnti-InflammatoriesAnti-Inflammatory AgentsAnti-inflammatoryAnti-viral TherapyAntibodiesAutoimmune StatusAutoimmunityBiological AgentBiological ProductsBlood NeutrophilBlood Polymorphonuclear NeutrophilBlood monocyteBone MarrowBone Marrow Reticuloendothelial SystemBp50CD134CD134LCD154CD40CD40LCD40LGCDW40CachectinCachectin ReceptorsCalcineurin antagonistCalcineurin inhibitorCancersCardiac DiseasesCardiac DisordersCardiovascular DiseasesCell Communication and SignalingCell FunctionCell PhysiologyCell ProcessCell SignalingCell TherapyCellular FunctionCellular Immune FunctionCellular PhysiologyCellular ProcessCessation of lifeChemotactic CytokinesChimera ProteinChimeric ProteinsClinical TrialsDeathDevelopmentDiabetes MellitusDialysisDialysis procedureDiseaseDisorderDrugsESKDESRDEffector CellEnd stage renal failureEnd-Stage Kidney DiseaseEnd-Stage Renal DiseaseEnvironmentFusion ProteinGP34Grafting ProcedureHealth Care CostsHealth CostsHeart DiseasesHomologous Chemotactic CytokinesHumanImmuneImmune Modulation TherapyImmune RegulatorsImmune ToleranceImmune responseImmunesImmunityImmunologic ToleranceImmunomodulationImmunomodulatorsImmunosuppressionImmunosuppression EffectImmunosuppressive EffectIndustryInfectionInflammatoryInflammatory ResponseInfusionInfusion proceduresInnate Immune ResponseInnate ImmunityIntercrinesIntracellular Communication and SignalingInvestigatorsIschemia-Reperfusion InjuryKidney GraftingKidney TransplantationKidney TransplantsMGC9013Macrophage-Derived TNFMaintenanceMalignant NeoplasmsMalignant TumorMarrow NeutrophilMarrow monocyteMedicationMemoryMesenchymal Progenitor CellMesenchymal Stem CellsMesenchymal progenitorMesenchymal stromal/stem cellsMinorityModern ManMonocyte-Derived TNFMorbidityMorbidity - disease rateMyeloid CellsMyeloid-derived suppressor cellsNHP modelsNative ImmunityNatural ImmunityNeutrophilic GranulocyteNeutrophilic LeukocyteNon-Specific ImmunityNonspecific ImmunityOX40OX40LOrganOrgan TransplantationOrgan TransplantsOutcomePathway interactionsPatient-Centered CarePatientsPharmaceutical PreparationsPolymorphonuclear CellPolymorphonuclear LeukocytesPolymorphonuclear NeutrophilsProductionPropertyProtocolProtocols documentationQOLQuality of lifeReagentRegimenRegulatory T-LymphocyteRenal GraftingRenal TransplantationRenal TransplantsReperfusion DamageReperfusion InjuryResearch PersonnelResearchersRoleSIS cytokinesScaffolding ProteinSelf ToleranceSignal TransductionSignal Transduction SystemsSignalingSolidSubcellular ProcessT cell responseT-Cell ActivationT-CellsT-LymphocyteTNFTNF ATNF AlphaTNF Receptor Family ProteinTNF Receptor SuperfamilyTNF ReceptorsTNF geneTNF-αTNFATNFRTNFRSF5TNFRSF5 geneTNFSF4TNFSF4 geneTNFSF5TNFSF5 geneTNFαTRAP GeneTXGP1TestingThinkingToxic effectToxicitiesTransplant RecipientsTransplantationTransplantation ToleranceTregTumor Necrosis FactorTumor Necrosis Factor ReceptorTumor Necrosis Factor Receptor FamilyTumor Necrosis Factor Receptor SuperfamilyTumor Necrosis Factor Receptor Superfamily Member 5 GeneTumor Necrosis Factor-alphaactivate T cellsadaptive immunityagesalloimmunityantigen-specific T cellsbiological signal transductionbiologicsbiopharmaceuticalbiotherapeutic agentcardiovascular disordercell based interventioncell mediated interventioncell mediated therapiescell-based therapeuticcell-based therapycellular therapeuticcellular therapychemoattractant cytokinechemokineclinical relevanceclinical translationclinically relevantclinically translatablecompare costcost comparisoncytokinedeath riskdevelopmentaldiabetesdialysis therapydonor antibodiesdonor-specific antibodydrug/agentexperiencegraft failureheart disorderhigh riskhost responseimmune check pointimmune checkpointimmune functionimmune modulationimmune modulatorsimmune modulatory therapiesimmune modulatory treatmentimmune regulationimmune regulation therapyimmune regulation treatmentimmune regulatory therapyimmune suppressionimmune suppressive activityimmune suppressive functionimmune system responseimmune system toleranceimmune unresponsivenessimmune-modulation treatmentimmunecheckpointimmunologic reactivity controlimmunological paralysisimmunomodulation therapyimmunomodulation treatmentimmunomodulator therapiesimmunomodulator treatmentimmunomodulator-based therapiesimmunomodulatoryimmunomodulatory biologicsimmunomodulatory moleculesimmunomodulatory therapiesimmunomodulatory treatmentimmunoregulationimmunoregulatorimmunoregulatoryimmunoregulatory moleculesimmunoregulatory therapyimmunoregulatory treatmentimmunoresponseimmunosuppressive activityimmunosuppressive functionimmunosuppressive myeloid cellsimmunosuppressive responseimprovedinfusionsinnovateinnovationinnovativeisoimmunitykidney txlife spanlifespanmalignancymembermesenchymal stromal cellmesenchymal stromal progenitor cellsmesenchymal-derived stem cellsmigrationmonocytemortality riskmyeloid suppressor cellsmyeloid-derived suppressive cellsneoplasm/cancerneutrophilnew drug treatmentsnew drugsnew pharmacological therapeuticnew therapeuticsnew therapynext generation therapeuticsnon-compliancenon-compliantnon-human primatenoncompliancenoncompliantnonhuman primatenonhuman primate modelsnovelnovel drug treatmentsnovel drugsnovel pharmaco-therapeuticnovel pharmacological therapeuticnovel therapeuticsnovel therapyorgan allograftorgan graftorgan xenograftp50pathwayprematureprematuritypreservationpreventpreventingregulatory T-cellsresponserestraintsafety assessmentside effectsocial rolesuppressive myeloid cellstherapeutic immunomodulationtherapeutic immunoregulationthoughtsthymus derived lymphocytetransplanttransplant modeltransplant patientviral infectious disease treatment
Description preview
Transplantation is the preferred treatment for patients suffering from end-stage kidney disease. While short-
term outcomes have greatly improved with the development of more effective immunosuppression, the long-
term outcomes remain problematic with life-span limiting complications including a significant number of
patients developing diabetes,…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click